The primary aim for EMIG is to ensure that patients have equal access to all health technologies.
This means that EMIG must work closely with government, regulators, the NHS and academic research establishments at all levels to create an environment, in which:
- The Government encourages pharmaceutical research and development (R&D) in the UK
- Pharmaceutical companies can operate effectively in delivering health technologies which have been proven safe and effective
- The decision to prescribe a technology is based on clinical need